Piramal Pharma Returns to Profit in Q2 FY27 as CDMO Revenue Jumps 36%, Raises FY27 Outlook
Piramal Pharma posted a ₹5 crore profit in Q2 FY27 against a year-ago loss, as revenue rose 28% to ₹2,617 crore on a 36% jump in CDMO sales; the company now guides for 19–20% revenue growth in FY27.
